NCT04866017 2024-10-31A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung CancerBeiGenePhase 3 Terminated63 enrolled 15 charts